What Are Peptides? What Patients Should Know Before Trying Peptide Therapy

Medically reviewed by the medical team at Nova Physician Wellness Center | August 2026

Key Points

• Peptides are short chains of amino acids that act as signaling molecules in the body. They occur naturally and regulate a wide range of biological processes including metabolism, hormone release, appetite, and tissue repair.
• GLP-1 medications like semaglutide (Wegovy) and tirzepatide (Zepbound) are technically peptides, and they are the only weight-related peptide therapies currently FDA approved for obesity treatment with large-scale clinical trial evidence.
• Many other peptides being marketed for weight loss and wellness, including BPC-157, CJC-1295, ipamorelin, and AOD-9604, are investigational. They do not have FDA approval and most have limited to no controlled human clinical trial data.
• The FDA's regulatory status of many compounded peptides changed significantly in 2023 and again in 2026 following a major policy announcement by HHS Secretary RFK Jr. The landscape is still evolving.
• Products sold online as "research use only" peptides carry documented risks of contamination, mislabeling, and inaccurate dosing with no physician oversight.
• Nova Physician Wellness Center does not currently prescribe investigational peptides. If you have questions about peptide therapy, we encourage you to bring them to a physician who can give you an honest, evidence-based answer.

Peptides are everywhere right now. Social media, wellness clinics, online forums, and direct-to-consumer advertising have made peptide therapy one of the most searched health topics of 2026. Patients are asking about BPC-157, CJC-1295, ipamorelin, AOD-9604, and a growing list of compounds being marketed for everything from weight loss and anti-aging to injury recovery and immune support.

At Nova Physician Wellness Center, our providers hear these questions regularly. And because we believe our patients deserve honest, medically accurate information rather than marketing language, this post gives you exactly that: a clear explanation of what peptides are, what the research actually shows, where the FDA stands right now, and what you need to know before pursuing any form of peptide therapy.

What Are Peptides?

A peptide is a short chain of amino acids. Amino acids are the building blocks of protein, and when they link together in specific sequences, they form molecules that act as signals throughout the body, telling cells, tissues, and organs how to behave.

Your body produces thousands of peptides naturally. They regulate an enormous range of biological functions including hormone release, immune response, appetite, metabolism, tissue repair, and sleep. In that sense, peptides are not exotic or foreign. They are a fundamental part of how your body communicates with itself.

The peptides used in medical and wellness contexts are synthetic versions of these naturally occurring molecules, designed in a lab to mimic or amplify specific biological signals. The idea, in theory, is to give your body more of a particular signal to produce a desired effect, whether that is increased growth hormone, accelerated tissue healing, enhanced metabolism, or reduced appetite.

That is the basic biology. What gets significantly more complicated is the question of which specific peptides have been proven to do what is claimed, in humans, safely, and at what dose.

The Peptide You Have Already Heard Of: GLP-1 Medications

Before we talk about the investigational peptides generating so much buzz, it is worth being clear about something that surprises many patients: the most effective weight loss medications available today are themselves peptides.

Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are synthetic peptides. Semaglutide mimics GLP-1, a gut hormone your body produces naturally after eating. Tirzepatide mimics both GLP-1 and GIP, a second gut hormone. These are GLP-1 medications in the clinical sense, but they are also technically peptide therapies in the biochemical sense.

The reason these medications are treated as the gold standard of weight loss treatment is not that they are peptides. It is that they are the only weight-related peptide therapies that have been through rigorous, large-scale, multi-year human clinical trials, received FDA approval based on that evidence, and demonstrated consistent and substantial weight loss of 15 to 21 percent or more of body weight in those trials.

That distinction, between a peptide that has been rigorously studied and approved versus one that is being marketed without that evidence base, is the most important thing to understand about the peptide landscape in 2026.

The Investigational Peptides Patients Are Asking About

Here is an honest overview of the most commonly discussed peptides in the wellness and weight loss space, along with what the evidence actually shows and where the FDA currently stands.

BPC-157 (Body Protection Compound)

BPC-157 is one of the most widely discussed peptides in wellness circles. It is derived from a protein found in gastric juice and has been marketed for gut healing, injury recovery, inflammation reduction, and anti-aging.

The FDA classifies BPC-157 as a substance with safety concerns. The agency has cited potential immunogenicity and manufacturing impurity risks as reasons for placing it in the restricted compounding category. Critically, BPC-157 has extensive animal research but almost no human controlled trial data. The evidence base for its effects in humans is primarily anecdotal and theoretical, not clinical. It is also banned by the World Anti-Doping Agency.

CJC-1295 and Ipamorelin

These two peptides are frequently paired together and marketed primarily for growth hormone support, body composition, improved sleep, and metabolic enhancement. CJC-1295 is a long-acting analog of growth hormone-releasing hormone (GHRH), meaning it signals the pituitary gland to release more growth hormone. Ipamorelin works through a different but complementary pathway to the same end.

The direct, controlled weight-loss evidence in healthy adults is limited, and these compounds are better understood as recovery and body-composition tools than weight-loss drugs. The FDA placed both on the restricted compounding list citing safety concerns.

AOD-9604

AOD-9604 is a fragment of human growth hormone that has been marketed specifically as a fat-burning peptide. It is one of the compounds with the longest list of regulatory concerns. The FDA has cited safety risks including potential carcinogenicity, immunogenicity, and concerns about impurities, and noted that most of these substances had never undergone rigorous human clinical trials. Compounding of AOD-9604 is currently prohibited.

Tesamorelin

Tesamorelin is the one peptide in this category with an actual FDA approval, though it is narrow and specific. Tesamorelin is a growth-hormone-releasing hormone analog approved to reduce visceral adipose tissue in a specific population. That specific population is adults with HIV-associated lipodystrophy, a condition where antiretroviral medications cause abnormal fat accumulation. It is not approved for general weight loss or obesity treatment in the broader population.

Sermorelin

Sermorelin is a growth hormone-releasing hormone analog that is legally compoundable in the United States. It is sometimes offered as an alternative to CJC-1295 given the regulatory constraints on that compound. Evidence for meaningful weight loss in healthy adults is limited. It is best understood as a body composition support tool rather than a primary weight loss intervention.

The 2026 Regulatory Picture: What Has Changed and What Hasn't

The regulatory landscape around peptides has shifted significantly in 2026, and patients deserve a clear explanation of where things actually stand.

The 2023 Restriction: In late 2023, the FDA placed approximately 19 widely used compounded peptides, including BPC-157, CJC-1295, ipamorelin, AOD-9604, and others, on its Category 2 restricted list. This effectively prohibited licensed compounding pharmacies from preparing and dispensing them. The agency cited safety risks including potential carcinogenicity, immunogenicity, and concerns about impurities, and noted that most of these substances had never undergone rigorous human clinical trials.

The February 2026 Announcement: On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides on the restricted list would be moved back to Category 1, restoring the legal pathway for licensed compounding pharmacies to prepare them under physician prescription. The peptides expected to return include BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, GHK-Cu, Selank, Semax, KPV, and MOTS-C, among others.

What This Does Not Mean: This policy shift is significant and is still working its way through formal FDA processes. It is essential to understand what it does and does not change. What is not on the FDA's approved list remains: BPC-157, CJC-1295, ipamorelin, AOD-9604, and the others under review. If compounding access is restored for these substances, they will still not be FDA-approved drugs. That distinction matters for patient safety, liability, and informed consent.

In other words, restoring the legal compounding pathway means these peptides can potentially be prescribed by a physician and prepared by a licensed pharmacy again. It does not mean they have been approved for safety and efficacy by the FDA, and it does not mean the underlying human clinical trial evidence has changed.

What Remains Restricted: Approximately five peptides including Melanotan II, GHRP-2, GHRP-6, LL-37, and PEG-MGF are expected to remain restricted due to ongoing safety concerns.

The Online Peptide Market: A Direct Warning

One of the most important things to understand about the current peptide landscape is the gap between the regulated pathway and what is actually being sold online.

Patients who had been using physician-prescribed peptide therapies did not stop when access was restricted. Many began sourcing from unregulated suppliers, overseas chemical vendors selling research-use-only compounds with no pharmaceutical manufacturing standards, no purity verification, no dosage accuracy, and no clinical oversight. Between 12 and 58 percent of unregulated supplement and research chemical products have been found to be contaminated with other substances.

Products sold online labeled as "research use only" peptides are not intended for human use. That label exists precisely because the manufacturer has not sought FDA approval for human administration. These products have no guaranteed purity, no verified concentration, no standardized dosing, and no regulatory quality control. Injecting a substance with unknown purity and concentration without physician oversight carries risks that are not theoretical.

This is not an argument against peptide therapy as a concept. It is an argument for accessing any peptide therapy, if and when it is appropriate, through a licensed physician with a prescription from a licensed compounding pharmacy, not through an online vendor.

How Peptide Therapy Differs From FDA-Approved Weight Loss Treatment

To bring this all together, here is the essential comparison patients need to understand before making any decisions:

The gap between these two categories is not a matter of opinion or preference. It is a matter of evidence. The most effective thing most patients searching for peptide therapy for weight loss can do right now is have a physician-supervised evaluation for FDA-approved treatment that has actually been proven to work.

What Nova Physician Wellness Center's Position Is

We want to be transparent with our patients about where we stand.

Nova Physician Wellness Center does not currently prescribe investigational peptides. Our obesity treatment approach is built around evidence-based, FDA-approved therapies including GLP-1 medications, combined with nutritional counseling, behavioral modification support, and physician-supervised monitoring through our comprehensive program.

We are following the evolving regulatory landscape around peptides closely. As the science develops and the regulatory picture becomes clearer, we will continue to evaluate whether any investigational therapies meet the evidence standard we require before offering them to patients. Our commitment is always to treatments that have been proven to be safe and effective, not simply available.

If you have questions about peptides you have seen advertised or heard about, we encourage you to bring those questions to your physician. You deserve honest, medically grounded answers, not marketing. That is exactly what our team provides.

Find Physician-Supervised Weight Loss Care in Northern Virginia and Maryland

If you have been researching peptide therapy for weight loss and are trying to figure out what actually works, the most productive first step is a conversation with a board-certified obesity medicine physician who can give you an accurate picture of your options based on your individual health.

Nova Physician Wellness Center has locations in Fairfax, Vienna (Tysons Corner), Arlington, Lansdowne, Sterling, Woodbridge, and Charlottesville in Virginia, and Rockville in Maryland. Telemedicine appointments are also available for patients across Virginia and Maryland. Most major insurance plans are accepted, including Medicare and Medicaid. You can verify your insurance coverage on our website.

Call (703) 865-6490 or visit novaphysicianwellness.com to schedule your consultation. New patients are always welcome.

Frequently Asked Questions About Peptides and Peptide Therapy

FAQs About Nova Physician Wellness Center 

Medical Disclaimer: The information in this blog post is for general educational purposes only and reflects publicly available clinical trial data and regulatory information as of August 2026. Retatrutide is an investigational drug that has not received FDA approval. It is not available for prescription outside of clinical trials. This post does not constitute medical advice, and nothing here should be used to make decisions about your own health or treatment. Please speak with a board-certified physician before making any changes to your weight management plan.